University of California

Otonomy, Inc.

Sova Pharmaceuticals, Inc.

Afraxis Holdings, Inc.

Afraxis, Inc.

Dompe' Farmaceutici S.p.a.

Sergio G Durón

Benedikt K Vollrath

Luis A Dellamary

Fabrice Piu

Qiang Ye

Jay Lichter

Carl Lebel

Andrew M Trammel

Jeffrey P Harris

Warren Stanfield Wade

Srinivas G Rao

Michael Christopher Scaife

Justin Chapman

Gregory Stein

Simon G Sydserff

David Alan Campbell

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-&#x3b3;-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Cystathionine-gamma-lyase (CSE) inhibitors

Cystathionine-&#x3b3;-lyase (CSE) inhibitors

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase ('ATPase') modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Provided herein are pyrido[2,3-D]pyrimidin-7(8H)-one compounds and compositions useful as PAK inhibitors. Also provided herein are methods of utilizing these compounds for the treatment of neuropsychiatric conditions. The compounds modulate dendritic spine morphology and/or synaptic function.

Compounds for treating neuropsychiatric conditions

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.

8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders

Growing community of inventors

San Diego, CA, United States of America

Sergio G Durón